STRIDES PHARMA SCIENCE LIMITED — Major Shareholding Notification 2020

Sep 21, 2020

Regd. Office : Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 I Fax: +91 80 4657 0400 I E-mail : info@agnus.in I www.agnus.in I LLPIN : AAA-3757

19 September 2020

To
BSE Limited	National Stock Exchange of India
Phiroze Jeejeebhoy Towers,	Exchange Plaza,
Dalal Street,	Bandra Kurla Complex,
Mumbai - 400 001	Bandra (E), Mumbai - 400 051

Scrip code: 532531 Scrip code: STAR

Ms. Manjula Ramamurthy Company Secretary & Compliance Officer Strides Pharma Science Ltd 201, Devavrata, Sector 17, Vashi, Navi Mumbai- 400703

Dear Sir/ Madam,

Sub: Disclosure under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to proposed inter-se transfer of equity shares of Strides Pharma Science Ltd

Pursuant to Regulation 10(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ('SEBI SAST Regulations'), kindly find enclosed herewith disclosure in the prescribed format with respect to proposed inter-se transfer acquisition of equity shares of Strides Pharma Science Ltd. The disclosure is being given on behalf of the promoter group and there would be no change in promoter holding consequent to such transfer.

Kindly take the same on record.

Thanking you, Yours faithfully,

For and on behalf of M/s Pronomz Ventures LLP [Promoter group Entity of Strides Pharma Science Ltd.]

_________________________________

Mr. Pudhucode Radhakrishnan Kannan Designated Partner

Encl.: A/a

Regd. Office : Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 I Fax: +91 80 4657 0400 I E-mail : info@agnus.in I www.agnus.in I LLPIN : AAA-3757

Disclosures under Regulation 10(5)- Intimation to Stock Exchanges in respect o f acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011

1.	Name of the Target Company (TC)	StridesPharma Science Ltd
2.	Name of the acquirer(s)	Pronomz Ventures LLP
3.	Whether the acquirer(s) is/ arepromoters of the TC prior to thetransaction.Ifnot,natureofrelationship or association with theTC or its promoters	Yes
4.	Details of the proposed acquisition
	a.Name of the person(s) fromwhom shares are to beacquired	Sequent Scientific Limited
	b.Proposed date of acquisition	25September2020 or thereafter
	c.Number of shares to beacquired from each personmentioned in 4(a) above	33,12,500shares
	d. Total shares to be acquired as %of share capital of the TC sharecapital of TC	3.70%
	e.Price at which shares areproposed to beAcquired	Rs. 475
	f.Rationale, if any, for theproposed transfer	Disposal of investment by Sequent Scientific Limited ('Sequent') inStrides Pharma Science Ltd through inter-se promoter transfer toPronomz Ventures LLP
5.	Relevant sub-clause of regulation10(1)(a) underwhich the acquirer is exemptedfrom making open offer	10(1)(a)(ii) of SEBI SAST Regulations
6.	If,frequentlytraded,volumeweighted average market price foraperiodof60tradingdayspreceding the date of issuance ofthis notice as traded on the stockexchange where the maximumvolume of trading in the shares ofthe TC are recorded during suchperiod.	Rs. 567.39
7.	If in-frequently traded, the price asdetermined in terms of clause (e) ofsub-regulation (2) of regulation 8.	Not Applicable

Regd. Office : Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 I Fax: +91 80 4657 0400 I E-mail : info@agnus.in I www.agnus.in I LLPIN : AAA-3757

8.9.	Declaration by the acquirer, thatthe acquisition price would not behigher by more than 25% of theprice computed in point 6 or point7 as applicable.Declaration by the acquirer, thatthe transferor and transferee havecomplied/willcomplywithapplicable disclosure requirementsin Chapter V oftheTakeoverRegulations, 2011	YesYes
	(corresponding provisions of therepealedTakeoverRegulations1997)
10.	Declaration by the acquirer that alltheconditionsspecifiedunderregulation 10(1)(a) with respect toexemptionshasbeendulycomplied with	Yes
11.	Shareholding details	Before the proposedtransaction		After the proposed transaction
		No. ofshares/votingrights	% wrt tototal sharecapital of TC	No. ofshares/votingrights	% wrt to totalshare capitalof TC
A	Acquirer(s) and PACs (other thansellers)(*)
(i)	Pronomz Ventures LLP	1,26,65,000	14.14%	1,59,77,500	17.84%
B	Seller (s)
(i)	Sequent Scientific Limited	33,12,500	3.70%	-	0.00%

(*) Shareholding of each entity may be shown separately and then collectively in a group. The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

Regd. Office : Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 I Fax: +91 80 4657 0400 I E-mail : info@agnus.in I www.agnus.in I LLPIN : AAA-3757

For and on behalf of M/s Pronomz Ventures LLP [Promoter group Entity of Strides Pharma Science Ltd.]

Signature: ______________________ (Mr. Pudhucode Radhakrishnan Kannan) Designated Partner

Date: 19 September 2020 Place: Bengaluru